Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma

Hepatology Research

Volumn 45, Issue 13, 2015, Pages 1283-1291

  Okusaka, Takuji ^a   Ueno, Hideki ^a   Ikeda, Masafumi ^b   Mitsunaga, Shuichi ^b   Ozaka, Masato ^c   Ishii, Hiroshi ^c   Yokosuka, Osamu ^d   Ooka, Yoshihiko ^d   Yoshimoto, Ryo ^e   Yanagihara, Yasuo ^f   Okita, Kiwamu ^g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d Otsuka Pharmaceutical ^*  (Japan)

^e CHIBA UNIVERSITY HOSPITAL   (Japan)

^f Fujii Memorial Research Institute   (Japan)

^g Shunan Memorial Hospital   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Dose escalation; OPB 31121; Phase 1 trial; Recommended dose; Signal transducer and activator of transcription 3 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; OPB 31121; PROTEIN INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CHILD PUGH SCORE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCURRENT INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GAIT DISORDER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHATIC SYSTEM DISEASE; MALAISE; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; NUTRITIONAL DISORDER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; THORAX DISEASE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84983201987     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12504     Document Type: Article

References (22)

1. Cancer Information Service, Center for Cancer Control and Information Services, National Cancer Center, Japan. Available at: http://ganjoho.ncc.go.jp/public/statistics/index.html. Accessed January 10, 2015.
2. Cancer Statistics 2010, Cancer Information Service, Center for Cancer Control and Information Services, National Cancer Center, Japan. Available at: http://ganjoho.jp/pro/statistics/en/backnumber/2010_en.html. Accessed August 25, 2014.
3. The Japan Society of Hepatology. Evidence-based Guideline on Liver Cancer Examination and Treatment, 2009. Tokyo: Kanehara & Co., Ltd., 2009.
4. The Japan Society of Hepatology. Clinical Practice Manual for Treating Liver Cancer: Second Edition. Tokyo: Igaku Shoin Ltd., 2010.
5. Kumada T, Nakano S, Takeda I et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
6. Uchiyama K, Ueno M, Hama T et al. Recurrence of primary hepatocellular carcinoma after hepatectomy - differences related to underlying hepatitis virus species. Hepatogastroenterology 2005; 52: 591-5.
7. Izumi N, Asahina Y, Noguchi O et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001; 91: 949-56.
8. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol 2013; 6: 90.
9. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol 2004; 22: 361-71.
10. Yu H, Jove R. The STATs of cancer - New molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
11. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007; 102: 311-9.
12. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296: 1653-5.
13. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3: 555-64.
14. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-23.
15. Hayakawa F, Sugimoto K, Harada Y et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J 2013; 3: e166.
16. Kim MJ, Nam HJ, Kim HP et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013; 335: 145-52.
17. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
18. Oh D-Y, Lee S-H, Han S-W et al. Phase I study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Canc Res Treat 2015; forthcoming.
19. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
20. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
21. Verstovsek S, Mesa RA, Gotlib J et al. A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
22. He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.